Brain+ (CPSE:BRAINP) - Stock Price, News & Analysis

BRAINP Stock Overview

Develops digital therapeutics for Alzheimer’s and dementia. More details

BRAINP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the Danish market

Latest financial reports are more than a year old

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (DKK21M)

Brain+ A/S Competitors

Monsenso

CPSE:MONSO

DKK 32.0m

NNIT

CPSE:NNIT

DKK 2.3b

nDatalyze

CNSX:NDAT

CA$4.0m

TALi Digital

ASX:TD1

AU$4.9m

Price History & Performance

Summary of all time highs, changes and price drops for Brain+
Historical stock prices
Current Share Price	DKK 0.099
52 Week High	DKK 0.24
52 Week Low	DKK 0.06
Beta	0
11 Month Change	1.02%
3 Month Change	15.93%
1 Year Change	-51.47%
33 Year Change	-96.89%
5 Year Change	n/a
Change since IPO	-97.75%

Recent updates

Shareholder Returns

	BRAINP	DK Healthcare Services	DK Market
7D	9.5%	0.6%	3.4%
1Y	-51.5%	-11.3%	7.5%

Return vs Industry: BRAINP underperformed the Danish Healthcare Services industry which returned -11.3% over the past year.

Return vs Market: BRAINP underperformed the Danish Market which returned 7.5% over the past year.

Price Volatility

Is BRAINP's price volatile compared to industry and market?
BRAINP volatility
BRAINP Average Weekly Movement	11.6%
Healthcare Services Industry Average Movement	5.9%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.5%

Stable Share Price: BRAINP's share price has been volatile over the past 3 months compared to the Danish market.

Volatility Over Time: BRAINP's weekly volatility has decreased from 17% to 12% over the past year, but is still higher than 75% of Danish stocks.

About the Company

Founded	Employees	CEO	Website
2012	n/a	Kim Baden-Kristensen	www.brain-plus.com

Brain+ A/S develops digital therapeutics for Alzheimer’s and dementia. It develops cognitive stimulation therapy (CST)-Assistant, a health tech solution to support scalable and delivery of group CST via a readily accessible preparation system, content adaptability and a standardized delivery form, which lessens the dependence of CST performance on therapists; CST - Home Care for use to extend and scale the delivery of CST to a home setting, enabling broader access to the therapy for a dementia population at limited costs; CST/ computerized cognitive training (CCT) combination product for individuals with mild cognitive impairment, combining cognitive stimulation therapy with computerized cognitive training to train cognitive function and potentially delay the transition to dementia; and Starry Night, a software based test designed to detect early signs of cognitive decline and enable early targeted intervention and treatment. Brain+ A/S was incorporated in 2012 and is based in Copenhagen, Denmark.

Brain+ A/S Fundamentals Summary

How do Brain+'s earnings and revenue compare to its market cap?
BRAINP fundamental statistics
Market cap	DKK 21.04m
Earnings (TTM)	-DKK 462.19k
Revenue (TTM)	DKK 6.08m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is BRAINP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BRAINP income statement (TTM)
Revenue	DKK 6.08m
Cost of Revenue	DKK 0
Gross Profit	DKK 6.08m
Other Expenses	DKK 6.55m
Earnings	-DKK 462.19k

Last Reported Earnings

Dec 31, 2018

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did BRAINP perform over the long term?

See historical performance and comparison

BRAINP Stock Overview

Risk Analysis

Brain+ A/S Competitors

CPSE:MONSO

DKK 32.0m

CPSE:NNIT

DKK 2.3b

CNSX:NDAT

CA$4.0m

ASX:TD1

AU$4.9m

Price History & Performance

Recent News & Updates

Brain+ A/S Launches Ayla - your CST Assistant into the UK Dementia Market

Brain+ A/S Confirms Imminent Commercial Launch of Ayla - Your CST Assistant as a Medical Device in the UK

Brain+ A/S Informs of Three Product Releases Planned for 2025 and Introduces A Platform Renaming as Part of Its UK Commercialization

First Patient Enters in A Clinical Trial to Evaluate Brain+' Next Generation Cognitive Training Technology for Mild Cognitive Impairment

Brain+ A/S Announces Results from UK Study of the CST Assistant Show Clinical Relevance, Cost-Benefits and Product-Market Fit

Brain+ A/S Announces Clinical Evaluation Report of the CST- Assistant Has Now Been Valued for UK Regulatory Compliance

Recent updates

Brain+ A/S Launches Ayla - your CST Assistant into the UK Dementia Market

Brain+ A/S Confirms Imminent Commercial Launch of Ayla - Your CST Assistant as a Medical Device in the UK

Brain+ A/S Informs of Three Product Releases Planned for 2025 and Introduces A Platform Renaming as Part of Its UK Commercialization

First Patient Enters in A Clinical Trial to Evaluate Brain+' Next Generation Cognitive Training Technology for Mild Cognitive Impairment

Brain+ A/S Announces Results from UK Study of the CST Assistant Show Clinical Relevance, Cost-Benefits and Product-Market Fit

Brain+ A/S Announces Clinical Evaluation Report of the CST- Assistant Has Now Been Valued for UK Regulatory Compliance

The Cst Assistant V2.0 for Cognitive Stimulation Therapy (Cst) Now Released in Denmark

Brain+ A/S Announces the Appointment of Devika Rani Wood as Chief Commercial Officer, Effective August 14, 2024

Brain+ Announces The CST-Assistant v2.0 is Now Ready for Release in Denmark and on Track for Release in the UK End of Third Quarter of 2024

Brain+ A/S Announces Election of Tim Juergens as New Board Member and Chairman

Brain+ A/S Provides Earnings Guidance for the Year 2024

Brain+ A/S to Report Fiscal Year 2023 Results on Apr 30, 2024

Brain+ A/S, Annual General Meeting, May 15, 2024

Brain+ A/S Announces CFO Changes

Brain+ A/S Announces Resignation of Anders Härfstrand as Chairman and Member of the Board, Effective from January 31, 2024

Brain+ Nominates to CO-PI Grant of Up to DKK 3.5 Million from Denmark's Business Promotion Board

Brain+ A/S Announces Resignation of Betül Susamis Unaran, Member of the Board of Directors, Effective on 30 November

Brain+ A/S Releases New Version of Its Cst-Therapist Companion Dementia Product with Updated User Features

Brain+ Secures Intellectual Property Rights for CST-Therapist Companion in the Eu and the United Kingdom

Brain+ A/S Provides Earnings Guidance for the Full Year 2023

Brain+ A/S Announces Breakthrough Alzheimer's Drug Approval Seen to Renew Dementia Drug Investments and Increase the Potential for Digital Dementia Therapeutics

No independent directors

Brain+ A/S Announces Board Resignation

Brain+ A/S Completes Swedish Research Version of Its Dementia Product with the Research Institutes of Sweden and Extends the Collaboration

Brain+ A/S Announces Results from Clinical Study Provide Promising Feasibility Indications for Brain+' CCT Technology for Cognitive Training

Brain+ A/S Announces 3-Year Innovation Project with the Danish Life Science Cluster Is Completed with the Brain+ CST-Therapist Companion Product as the Final Output

Less than half of directors are independent

Brain+ Announces Board Appointments

Brain+ Announces Its First Digital Dementia Product, Cognitive Stimulation Therapy (CST)-Therapist Companion

Less than half of directors are independent

Brain+ A/S Approves Board Changes

Brain+' New Digital Product for Dementia, “CST-Therapist Companion” Is Ready for Commercial Launch in Denmark

Brain+ A/S Announces Retirement of Jonas Nilsen from the Board

Kim Arvid Nielsen Decides to Step Down from the Board of Brain+ A/S

Paula Petcu Joins Brain+ as New Chief Technology Officer

Brain+ A/S Announces Publication of Results from an Earlier Study That Showed Cognitive Improvements in People with Brain Injury After Training with Brain+ Recover Computerized Cognitive Training Product

Positive Results from the First of Four Clinical Studies to Evaluate Brain+' Starry Night Cognitive Test for Early Detection of Alzheimer's Disease

Brain+ A/S Appoints Bertil S. Jessen as Chief Financial Officer, Effective March 1, 2022

Shareholder Returns

Price Volatility

About the Company

Brain+ A/S Fundamentals Summary

0.0x

0.0x

Earnings & Revenue